General Information of DTT (ID: TT9W8GU)

DTT Name Gamma-secretase (GS) DTT Info
UniProt ID
APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN
Gene Name APH1A; APH1B; NCSTN; PSENEN; PSEN1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
18 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [1]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [2]
PF-03084014 DMUP5Z0 Desmoid tumour 2F7C Phase 3 [3]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [4]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [5]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [6]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [7]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [8]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [1]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [9], [10]
Begacestat DMUR49N Alzheimer disease 8A20 Phase 1 [11]
E-2212 DMQDKYV Alzheimer disease 8A20 Phase 1 [12]
E2012 DMNEVKA Alzheimer disease 8A20 Phase 1 [13], [14]
GSI-136 DMSR5HD Alzheimer disease 8A20 Phase 1 [15]
NGP 555 DMTVQH2 Alzheimer disease 8A20 Phase 1 [16]
PF-06648671 DMGUKRN Alzheimer disease 8A20 Phase 1 [16]
PF-06648671 DM056JD Alzheimer disease 8A20 Phase 1 [17]
SPI-014 DM5IPUS Alzheimer disease 8A20 Phase 1 [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Clinical Trial Drug(s)
8 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O Discovery agent N.A. Investigative [19]
(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone DMREVX9 Discovery agent N.A. Investigative [19]
(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU Discovery agent N.A. Investigative [19]
1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T Discovery agent N.A. Investigative [19]
Drug 311383 DM5QUJV Discovery agent N.A. Investigative [20]
Drug 311440 DMOIFBK Discovery agent N.A. Investigative [20]
Drug 311951 DMXTCJ1 Discovery agent N.A. Investigative [20]
Drug 311952 DM27ILS Discovery agent N.A. Investigative [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Investigative Drug(s)
Molecule Interaction Atlas

References

1 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
2 Clinical pipeline report, company report or official report of Roche (2009).
3 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
4 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
5 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
6 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
7 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
8 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
9 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
10 Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.Cancer.2015 Feb 1;121(3):432-440.
11 Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608.
12 Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry. 2013 May 14;52(19):3197-216.
13 Chemical Biology, Molecular Mechanism and Clinical Perspective of -Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol.2011 Dec;9(4):598-622.
14 Lactams as beta secretase inhibitors
15 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Pharmacokinetic and Pharmacodynamic Effects of a -Secretase Modulator, PF-06648671, on CSF Amyloid- Peptides in Randomized Phase I Studies. Clin Pharmacol Ther. 2020 Jan;107(1):211-220.
18 Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.
19 Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
20 Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.